DNA Unlocked: Beyond Genomics

Genomics is just one branch in the burgeoning field of science informally known as -omics. The data points flowing from various branches of omics can be pieced together to build a sharper picture of how disease takes root and develops. The technology has the potential to deliver new biomarkers for earlier diagnosis of disease, faster and more successful clinical trials, and the ability to predict and prevent disease before it becomes more grievous and costly.

In this episode, we talk to Larry Gold, founder of SomaLogic, a company with technology that provides more coverage of the proteome than any other platform. This technology is based on aptamers—nucleic acid molecules that bind to precise targets. Prior to SomaLogic, Gold founded and was chairman of NeXagen, which later became NeXstar Pharmaceuticals.

To dive further into this topic, please join Amgen scientists at the DNA Unlocked Q&A webinar discussion on September 8, 2021. Register for this event here: DNA Unlocked Q&A

 

DNA Unlocked is a special edition podcast series produced by The Scientist’s Creative services Team. This series is brought to you by Amgen, which is a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.

Since the initial sequencing of the human genome almost twenty years ago, researchers have been enticed by an explosion of DNA data. These sequences hold the promise of understanding human biology, transforming drug research and development, and curing diseases. However, the quest to generate insights from human genetics and -omics research has been full of twists, turns, and roadblocks. In DNA UNLOCKED, Ray Deshaies, senior vice president of Global Research at Amgen, explores the ever-evolving perception of human biology and disease processes thanks to a growing mountain of genetics and omics data. Through discussions with colleagues and other leading research experts, Deshaies unpacks how drug developers decode human genetics to solve some of the most challenging diseases.